An open-label, Phase I study of cediranib (RECENTIN (TM)) in patients with acute myeloid leukemia

作者：Fiedler Walter^*; Mesters Rolf; Heuser Michael; Ehninger Gerhard; Berdel Wolfgang E; Zirrgiebel Ute; Robertson Jane D; Puchalski Tom A; Collins Barbara; Juergensmeier Juliane M; Serve Hubert

来源：Leukemia Research, 2010, 34(2): 196-202.

DOI：10.1016/j.leukres.2009.07.020

• Acute myeloid leukemia
• Cediranib
• Angiogenesis
• Vascular endothelial growth factor

VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN (TM)), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of <= 30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy.

• 出版日期2010-2